In one paragraphArticle in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Anfal AbdelgadirDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5345-9972 Edgar F KongDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-8810-977X Michael L MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Boyd L YountDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Trevor ScobeyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
John M PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-0485-9109 Kendra L GullyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5742-2341 Lily E AdamsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Katayoun MansouriDuke Human Vaccine Institute, Durham, NC, USA.
Priyanka DevkotaDuke Human Vaccine Institute, Durham, NC, USA.
Katarzyna JanowskaDuke Human Vaccine Institute, Durham, NC, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-0210-8440 Abbey L BiggersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jason J LavinderDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-6044-1332 Gregory C IppolitoTexas Biomedical Research Institute, San Antonio, TX, USA.
Mark T HeiseDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5829-8477 Lisa E GralinskiDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-1374-8002 Ralph S BaricDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-6827-8701 Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MResearch Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5MSpecific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0MProject 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2023
$28.0MVector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Scott H Randell · 2004 to 2026
$26.5MStructure-based design of broadly protective coronavirus vaccinesP01AI167966 · NIAID · UNIVERSITY OF WASHINGTON · PI BALI PULENDRAN · 2022 to 2026
$15.3MMolecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7MEffect of natural and engineered variations on structure and biophysics of SARS-CoV-2 spikeR01AI165947 · NIAID · DUKE UNIVERSITY · PI Priyamvada Acharya, Rory Henderson · 2022 to 2026
$3.8MBill & Melinda Gates Foundation INV-006133NCI NIH HHS P30 CA016086NIAID NIH HHS P01 AI158571NIAID NIH HHS P01 AI167966NIAID NIH HHS R01 AI165947NIAID NIH HHS T32 AI007419NIAID NIH HHS U19 AI142790NIAID NIH HHS U19 AI171292NIDDK NIH HHS P30 DK065988
6 · The paper itselfAbstract
Zoonotic Sarbecoviruses present a documented threat to global health. Here, we report the recovery of an African clade-3 recombinant Sarbecovirus, PRD0038, and derivatives encoding reporter genes. Cryo-EM structural analyses of rPRD0038 revealed spike glycoprotein sites that facilitate the receptor-binding domain (RBD)-up conformation, enhancing replication in
Indexed as
antiviralCoronavirusepidemiologyPRD0038SarbecovirusSpike
Identifiers
PMID42427868
PMCPMC13345557
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390